XML 52 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
ACQUISITIONS, DIVESTITURES AND LICENSING ARRANGEMENTS(Tables)
 12 Months Ended
Dec. 31, 2017
Acquisitions and Divestitures [Abstract]  
Schedule of Asset Acquisitions, by Acquisition [Table Text Block]
Dollars in Millions
 
Year
 
Upfront Payment
 
R&D Expense
 
Deferred Tax Assets(a)
 
Contingent Consideration
IFM(b)
 
2017
 
$
325

 
$
311

 
$
14

 
$
2,020

 
 
 
 
 
 
 
 
 
 
 
Cormorant
 
2016
 
35

 
35

 
—

 
485

Padlock
 
2016
 
150

 
139

 
11

 
453

 
 
 
 
$
185

 
$
174

 
$
11

 
$
938

 
 
 
 
 
 
 
 
 
 
 
Cardioxyl
 
2015
 
$
200

 
$
167

 
$
33

 
$
1,875

Flexus(c)
 
2015
 
814

 
800

 
14

 
450

 
 
 
 
$
1,014

 
$
967

 
$
47

 
$
2,325

(a)
Relates to net operating loss and tax credit carryforwards.
(b)
Includes $25 million for certain negotiation rights to collaborate, license or acquire an NLRP3 antagonist program from a newly formed entity established by the former shareholders of IFM.
(c) Includes $14 million of acquisition costs.
Disposal Groups, Including Discontinued Operations [Table Text Block]
Divestitures
 
Proceeds(a)
 
Divestiture (Gains) / Losses
 
Royalty (Income)
Dollars in Millions
2017
 
2016
 
2015
 
2017
 
2016
 
2015
 
2017
 
2016
 
2015
Investigational HIV medicines
$
—

 
$
387

 
$
—

 
$
(11
)
 
$
(272
)
 
$
—

 
$
—

 
$
—

 
$
—

OTC brands (Reckitt)
—

 
317

 
—

 
—

 
(277
)
 
—

 
—

 
—

 
—

Diabetes
405

 
333

 
374

 
(126
)
 
—

 
(82
)
 
(329
)
 
(361
)
 
(215
)
Erbitux*
218

 
252

 
9

 
—

 
—

 
171

 
(224
)
 
(246
)
 
(70
)
Recothrom*
—

 
—

 
132

 
—

 
—

 
(59
)
 
—

 
—

 
—

Mature brand products (Valeant)
—

 
—

 
61

 
—

 
—

 
(88
)
 
—

 
—

 
—

Ixempra*
4

 
13

 
113

 
—

 
—

 
(88
)
 
(4
)
 
(11
)
 
(8
)
Other
24

 
15

 
8

 
(24
)
 
(15
)
 
(48
)
 
—

 
—

 
—

 
$
651

 
$
1,317

 
$
697

 
$
(161
)
 
$
(564
)
 
$
(194
)
 
$
(557
)
 
$
(618
)
 
$
(293
)
(a)
Includes royalties received subsequent to the related sale of the asset or business.